PALYNZIQ® (pegvaliase-pqpz) Injection - A Phe-lowering Enzyme Therapy for Adults With PKU
Dr. Barbara Burton and Heather Bausell, RD, LDN, provide a detailed overview of PALYNZIQ’s safety profile, including data showing how the rates of the 3 most common adverse reactions decrease from induction/titration to maintenance, regardless of the specific maintenance dose (20 mg, 40 mg, or 60 mg).
PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.
Please see full Prescribing Information, with Boxed Warning for risk of anaphylaxis, and Medication Guide, here.
Listen to PKU experts review PALYNZIQ’s safety and efficacy, and discuss the clinical considerations that their team evaluates when administering PALYNZIQ.
Listen to one clinic’s considerations during the initial screening of adult patients with PKU for starting PALYNZIQ treatment.
Hear how a Nurse Practitioner and Registered Dietitian provide ongoing care to adult PKU patients during their treatment with PALYNZIQ.
PKU experts discuss PALYNZIQ’s mechanism of action and long-term efficacy data.
PKU experts share PALYNZIQ’s dosing and administration, including dose options up to 60 mg once daily.
Watch a discussion of unique adult PKU patient case studies, including considerations taken to manage these patients using PALYNZIQ.
This educational video helps patients learn about the potential for a severe allergic reaction with PALYNZIQ.
This video helps address patient fears about needles and injections by reviewing specific product information, and the support they’ll receive with PALYNZIQ.
Get to know Sarah and learn about her experience starting PALYNZIQ.
Patients can learn how the immune system responds to PALYNZIQ.